{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:35:11Z","timestamp":1775741711016,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jdiacomp.2026.109308","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:58:01Z","timestamp":1772207881000},"page":"109308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre-treatment estimated glomerular filtration rate trajectory modifies the renoprotective effect of finerenone in patients with chronic kidney disease associated with type 2 diabetes"],"prefix":"10.1016","volume":"40","author":[{"given":"Takamasa","family":"Iwamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyuki","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2026.109308_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-47091-y","article-title":"Global burden and influencing factors of chronic kidney disease due to type 2 diabetes in adults aged 20\u201359 years, 1990\u20132019","volume":"13","author":"Xie","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112326","article-title":"Screening, prevalence, and burden of chronic kidney disease in people with type 2 diabetes managed by endocrinologists: a nationwide cross-sectional study","volume":"226","author":"Mart\u00ednez-Montoro","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0015","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0020","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/dom.15765","article-title":"Chronic kidney disease in type 2 diabetes: the size of the problem, addressing residual renal risk and what we have learned from the CREDENCE trial","volume":"26","author":"Chaudhry","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0030","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0035","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0045","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0050","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0055","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0060","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0065","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2337\/dci23-0030","article-title":"Diabetic nephropathy: update on pillars of therapy slowing progression","volume":"46","author":"Naaman","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0070","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","article-title":"A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors","volume":"33","author":"Sen","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0075","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0080","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0085","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/kisup.2012.65","article-title":"Definition, identification, and prediction of CKD progression","volume":"3","year":"2013","journal-title":"Kidney Int Suppl (2011)."},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0095","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0100","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10157-023-02376-4","article-title":"eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database","volume":"27","author":"Itano","year":"2023","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","article-title":"The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference","volume":"99","author":"Shlipak","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002125","article-title":"Burden of chronic kidney disease and rapid decline in renal function among adults attending a hospital-based diabetes center in northern Europe","volume":"9","author":"Griffin","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0115","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/jdi.13795","article-title":"Renoprotective effect of additional sodium-glucose cotransporter 2 inhibitor therapy in type 2 diabetes patients with rapid decline and preserved renal function","volume":"13","author":"Sada","year":"2022","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0120","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000902","article-title":"Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan","volume":"8","author":"Yoshida","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0125","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1681\/ASN.2015111264","article-title":"Pragmatic clinical trials in CKD: opportunities and challenges","volume":"27","author":"de Boer","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0130","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1681\/ASN.0000000000000412","article-title":"Clinical trials for kidney disease in the era of personalized medicine","volume":"35","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0135","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0145","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.ekir.2025.04.012","article-title":"Finerenone and estimated GFR slope in type 2 diabetes and CKD","volume":"10","author":"Yamanouchi","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0150","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/ajh.2011.245","article-title":"Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension","volume":"25","author":"Shibata","year":"2012","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0155","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/dom.14986","article-title":"Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: a systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Maddaloni","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0160","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.clinthera.2024.04.009","article-title":"No differences in kidney function decline between people with type 2 diabetes starting a sodium-glucose cotransporter 2 inhibitor or a glucagon-like peptide-1 receptor agonist: a real-world retrospective comparative observational study","volume":"46","author":"Bodini","year":"2024","journal-title":"Clin Ther"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2024.100318","article-title":"Efficacy and safety of finerenone in individuals with type 2 diabetes mellitus complicated by diabetic kidney disease: a retrospective observational study","volume":"24","author":"Kawaguchi","year":"2024","journal-title":"Metabol Open"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0170","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.111.173195","article-title":"Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralocorticoid receptors","volume":"59","author":"Fu","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0175","doi-asserted-by":"crossref","first-page":"F427","DOI":"10.1152\/ajprenal.00072.2014","article-title":"Aldosterone sensitizes connecting tubule glomerular feedback via the aldosterone receptor GPR30","volume":"307","author":"Ren","year":"2014","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0185","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0190","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0195","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1053\/j.ajkd.2018.04.023","article-title":"Biological variability of estimated GFR and albuminuria in CKD","volume":"72","author":"Waikar","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0200","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0205","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41440-022-01036-6","article-title":"Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification","volume":"46","author":"Jo","year":"2023","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0210","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1536\/ihj.16-649","article-title":"High glucose stimulates mineralocorticoid receptor transcriptional activity through the protein kinase C \u03b2 signaling","volume":"58","author":"Hayashi","year":"2017","journal-title":"Int Heart J"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.mce.2018.01.007","article-title":"Epidermal growth factor receptor\/extracellular signal-regulated kinase pathway enhances mineralocorticoid receptor transcriptional activity through protein stabilization","volume":"473","author":"Mitsuishi","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0220","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41440-020-00562-5","article-title":"CASZ1b is a novel transcriptional corepressor of mineralocorticoid receptor","volume":"44","author":"Yokota","year":"2021","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0225","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41440-022-01131-8","article-title":"CASZ1: a promising factor modulating aldosterone biosynthesis and mineralocorticoid receptor activity","volume":"46","author":"Yokota","year":"2023","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0230","doi-asserted-by":"crossref","first-page":"e1624","DOI":"10.1210\/clinem\/dgad358","article-title":"Associations of diabetic retinopathy severity with high ambulatory blood pressure and suppressed serum renin levels","volume":"108","author":"Sada","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2026.109308_bb0235","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1681\/ASN.2022030306","article-title":"Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD","volume":"33","author":"Jongs","year":"2022","journal-title":"J Am Soc Nephrol"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105687272600053X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105687272600053X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:35:04Z","timestamp":1775738104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105687272600053X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S105687272600053X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109308","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-treatment estimated glomerular filtration rate trajectory modifies the renoprotective effect of finerenone in patients with chronic kidney disease associated with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"109308"}}